☆ 4.5 Article

Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series

INFECTIOUS DISEASES AND THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy

Eric Wenzler et al.

Summary: The study evaluated the PK and PD of cefiderocol during CRRT and provided optimal dosing recommendations. Effluent flow rate was identified as the primary driver of clearance during CRRT, and optimal cefiderocol doses were calculated to match systemic exposure. The developed dosing regimens have been incorporated into the prescribing information for cefiderocol, making it the first antimicrobial with labeled dosing for CRRT.

CLINICAL PHARMACOKINETICS (2022)

Add to Collection

Article Infectious Diseases

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

Emanuele Rando et al.

Summary: This study retrospectively described 13 cases of carbapenem-resistant A. baumannii pneumonia treated with cefiderocol in real-life practice, with a 30-day success rate of 54%. The findings suggest that cefiderocol may have a role in severe XDR A. baumannii pneumonia.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Review Pharmacology & Pharmacy

Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review

Riyan Babidhan et al.

Summary: This systematic review examines the safety and efficacy of off-label use of cefiderocol for various infections, particularly for Pseudomonas aeruginosa and Acinetobacter baumannii infections. Combination antibiotic therapy was commonly used, and cefiderocol-related side effects were rare.

PHARMACOTHERAPY (2022)

Add to Collection

Review Infectious Diseases

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance

Stamatis Karakonstantis et al.

Summary: Cefiderocol is a promising drug that can overcome most beta-lactam resistance mechanisms. Resistance is uncommon but alarming proportions have been reported in recent cohorts. Various mechanisms, especially the coexpression of multiple beta-lactamases, contribute to resistance. Heteroresistance is prevalent in Acinetobacter baumannii, but its clinical impact is still uncertain.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Pharmacology & Pharmacy

Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement Therapy

Xiaohui Wei et al.

Summary: In this report, we describe our scientific approach for including effluent flow rate (Q(E))-based dosing recommendations of cefiderocol for patients receiving continuous renal replacement therapy (CRRT) in the product labeling. The total clearance (CL) of cefiderocol in CRRT patients was estimated by considering both nonrenal and extracorporeal clearance. The dosing regimens for CRRT patients were determined to achieve similar pharmacokinetic profiles as patients not receiving CRRT.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Infectious Diseases

Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis

Wesley D. Kufel et al.

Summary: The study investigated the pharmacokinetics of cefiderocol in cerebrospinal fluid (CSF) and plasma during the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) meningitis using two different dosing regimens. Results showed that cefiderocol achieved CSF concentrations surpassing the organism-specific MIC and the CLSI susceptible breakpoint for 100% of the dosing interval, leading to microbiological and clinical cure without any adverse effects.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Immunology

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients

Marco Falcone et al.

Summary: In this study, cefiderocol was used to treat patients with bacteremia or ventilator-associated pneumonia caused by drug-resistant strains, showing a 70% clinical success rate and 90% survival rate. However, two patients experienced microbiological failure, highlighting the need for future prospective studies to further evaluate the effectiveness of the treatment.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Immunology

Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections

Nathaniel C. Warner et al.

Summary: Treatment options for Achromobacter xylosoxidans are limited, but clinical response was observed after cefiderocol treatment. However, microbiologic relapse was common after treatment, notably without emergence of resistance.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices

Marta Bodro et al.

Summary: This study describes two challenging cases of intravascular foreign body infections caused by multidrug-resistant Gram-negative pathogens successfully treated with complex antimicrobial regimens including cefiderocol without implant removal. The cases highlight the potential of cefiderocol as a promising drug for treating foreign body infections caused by MDR Gram-negative pathogens.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection

Article Microbiology

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study

Alexandre Bleibtreu et al.

Summary: Cefiderocol, a novel siderophore cephalosporin, has shown in vitro activity against carbapenem-resistant Gram-negative pathogens and stability towards all carbapenemases. This study in France aimed to describe the first cases of compassionate use of cefiderocol and its efficacy, revealing a need for caution in using orphan drugs during this period; mainly targeting respiratory tract infections.

MICROORGANISMS (2021)

Add to Collection

Article Infectious Diseases

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

Milo Gatti et al.

Summary: The study shows that suboptimal attainment of PK/PD targets of cefiderocol may lead to microbiological failure of treatment with cefiderocol in critically ill patients affected by XDR-AB VAP.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections

Yahiya Y. Syed

Summary: Cefiderocol is a cephalosporin with activity against carbapenem-resistant bacteria and nonfermenters, using the bacteria's iron uptake system to disrupt the cell wall and kill the bacteria. It has shown good effectiveness and safety in clinical trials for various serious bacterial infections, providing a useful addition to treatment options for adults with limited choices.

DRUGS (2021)

Add to Collection

Article Infectious Diseases

Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia

Takayuki Katsube et al.

Summary: This study assessed the intrapulmonary pharmacokinetic profile of cefiderocol in hospitalized, mechanically ventilated pneumonia patients, showing that cefiderocol can penetrate the epithelial lining fluid in the lungs with concentrations sufficient to treat Gram-negative bacteria.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol-Based Combination Therapy for Difficult-to-Treat Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Davide Fiore Bavaro et al.

Summary: This study investigated the efficacy of cefiderocol-based combination therapies as rescue treatments for eradicating severe infections caused by multidrug-resistant bacteria. Most patients were immunocompromised or critically ill, and showed good treatment outcomes during the course of therapy, with some deaths attributed to other causes.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Infectious Diseases

Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance

Christina Koenig et al.

Summary: Cefiderocol is a novel siderophore-cephalosporin used for treating multi-drug resistant Gram-negative pathogens, primarily in critically ill patients. Despite effective dosing instructions, therapeutic drug monitoring and dose adjustment may be necessary, especially in the presence of a cytokine adsorber, to maintain drug levels in vulnerable patient populations such as those with septic shock and renal failure.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Infectious Diseases

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections

Marianna Meschiari et al.

Summary: This study describes the real-life experience of using cefiderocol in XDR and difficult-to-treat resistant Pseudomonas aeruginosa infections without other treatment options available. Clinical cure and microbiological cure rates were 70.6% and 76.5% respectively, with a mortality rate of 35.3%.

JAC-ANTIMICROBIAL RESISTANCE (2021)

Add to Collection

Article Immunology

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Pranita D. Tamma et al.

Summary: This guidance document provides recommendations for the treatment of antimicrobial-resistant infections caused by ESBL-E, CRE, and DTR-P. aeruginosa, with a focus on the United States. It discusses empiric treatment selection, duration of therapy, and other management considerations for both adults and children. The current version of the guidance is valid as of September 17, 2020, and will be updated periodically.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Critical Care Medicine

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

Mohd H. Abdul-Aziz et al.

INTENSIVE CARE MEDICINE (2020)

Add to Collection

Article Immunology

Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature

Sandra Zingg et al.

Open Forum Infectious Diseases (2020)

Add to Collection

Article Infectious Diseases

Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii

Alessandra Oliva et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

George G. Zhanel et al.

DRUGS (2019)

Add to Collection

Article Immunology

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

Yoshinori Yamano

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Article Immunology

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin

Takayuki Katsube et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

Krystyna M. Kazmierczak et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)

Add to Collection

Article Chemistry, Medicinal

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

Toshiaki Aoki et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)

Add to Collection

Article Infectious Diseases

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli et al.

LANCET INFECTIOUS DISEASES (2018)

Add to Collection

Article Microbiology

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Akinobu Ito et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

Add to Collection

Article Infectious Diseases

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

A. -P. Magiorakos et al.

CLINICAL MICROBIOLOGY AND INFECTION (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.